Tryptamine Therapeutics Limited
TYPTF
$0.01
$0.00-6.67%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -418.40K | -409.70K | -1.31M | -1.35M | -850.10K |
| Total Depreciation and Amortization | 10.90K | 10.70K | 6.60K | 6.80K | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 395.20K | 387.00K | -333.60K | -343.00K | 152.50K |
| Change in Net Operating Assets | -865.40K | -847.40K | -- | -- | -12.20K |
| Cash from Operations | -877.70K | -859.50K | -1.64M | -1.69M | -709.70K |
| Capital Expenditure | -2.70K | -2.70K | -39.30K | -40.40K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.30K | -1.30K | -- | -- | -- |
| Cash from Investing | -4.10K | -4.00K | -39.30K | -40.40K | -- |
| Total Debt Issued | -- | -- | -- | -- | 2.67M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.63M | 1.63M | 1.38M | 1.38M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -103.00K | -103.00K | -98.70K | -98.70K | -- |
| Cash from Financing | 975.00K | 954.70K | 831.70K | 855.20K | 1.95M |
| Foreign Exchange rate Adjustments | -29.60K | -28.90K | 32.00K | 32.90K | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 63.70K | 62.40K | -814.50K | -837.50K | 1.24M |